BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2026 3:41:45 AM | Browse: 26 | Download: 80
 |
Received |
|
2025-09-18 02:18 |
|
Peer-Review Started |
|
2025-09-18 02:18 |
|
First Decision by Editorial Office Director |
|
2025-10-21 07:29 |
|
Return for Revision |
|
2025-10-21 07:29 |
|
Revised |
|
2025-10-21 13:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-22 02:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-22 08:58 |
|
Articles in Press |
|
2026-01-22 08:58 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-04 00:41 |
|
Publish the Manuscript Online |
|
2026-02-11 03:41 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Risankizumab redefines Crohn’s treatment after ustekinumab failure
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Felix Pius Omullo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Felix Pius Omullo, Department of Medical Services, Equity Afya, Kiharu Township, Lodwar 399-30500, Turkana, Kenya. piuskirasia@gmail.com |
| Key Words |
Crohn disease; Ustekinumab; Risankizumab; Interleukin-23; Drug substitution; Treatment failure; Secondary loss of response; Biological therapy |
| Core Tip |
Emerging real-world data indicate that risankizumab may induce high rates of clinical and biomarker remission after ustekinumab failure in Crohn’s disease. These findings challenge the traditional cross-class switching paradigm and suggest potential for sequential, increasingly specific interleukin-23 pathway blockade. While mechanistically plausible, the evidence remains preliminary from single-center studies. Balanced interpretation, validation in larger diverse cohorts, and rigorous cost-effectiveness analyses are needed before revising global treatment algorithms. |
| Publish Date |
2026-02-11 03:41 |
| Citation |
Omullo FP. Risankizumab redefines Crohn’s treatment after ustekinumab failure. World J Gastrointest Pharmacol Ther 2026; 17(1): 114412 |
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i1/114412.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v17.i1.114412 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
